Sagimet Biosciences Inc. Series A Common Stock (SGMT)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Sagimet Biosciences Inc. Series A Common Stock.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 1 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 7.10 $ — 50% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 269.0% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 7
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -1.22 | -1.51 – -0.89 | 0 | 22.7% | 9 |
| 12/31/2027 | -1.31 | -1.80 – -0.62 | 8 | -7.3% | 9 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.28 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.26 | – | 0 | – | – | -11 | -11 |
| 2025: Q1 | -0.30 | – | 0 | – | – | -15 | -15 |
| 2025: Q2 | -0.17 | – | 0 | – | – | -9 | -9 |
| 2025: Q3 | -0.21 | – | 0 | – | – | -10 | -10 |
| 2025: Q4 | -0.16 | – | 0 | – | – | -12 | -12 |
| 2026: Q1 | -0.17 | – | 0 | – | – | -9 | -9 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2019 | 0 | -14 | -14 | -0.64 | -11 | -125 | 11 |
| 2020 | 0 | -11 | -11 | -0.51 | -10 | -136 | 69 |
| 2021 | 0 | -24 | -24 | -1.10 | -22 | -158 | 59 |
| 2022 | 0 | -31 | -31 | -1.38 | -24 | -187 | 33 |
| 2023 | 2 | -31 | -28 | -1.53 | -24 | 91 | 97 |
| 2024 | 0 | -54 | -46 | -1.45 | -42 | 156 | 160 |
| 2025 | 0 | -57 | -51 | -1.58 | -46 | 111 | 116 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Sagimet Biosciences Inc., ein biopharmazeutisches Unternehmen in der klinischen Phase, entwickelt neuartige Therapeutika namens Fettsäuresynthase-(FASN-)Inhibitoren zur Behandlung von Erkrankungen, die aus gestörten metabolischen und fibrotischen Signalwegen resultieren, in den USA.
| Employees | 16 |
|---|---|
| Headquarters | San Mateo, CA |
| Address | 155 Bovet Road, 94402 San Mateo, United States |
| Phone | 650 561 8600 |
| Website | sagimet.com |
| IPO Date | 14. Jul 2023 |
| ISIN | US7867001049 |
Management
| Name | Title | Birth Year |
|---|---|---|
| David A. Happel | CEO, President & Director | 1962 |
| Elizabeth Rozek Esq., J.D. | Chief Legal & Administrative Officer | 1972 |
| Urs Greber Ph.D. | Co-Founder | – |
| Lucas Pelkmans Ph.D. | Co-Founder | – |
| Thierry Chauche | CFO & Principal Accounting Officer | 1976 |
| Marie O'Farrell Ph.D. | Chief Scientific Officer | – |
| Robert D'Urso | Senior Vice President of New Products | – |
| Andreas Grauer M.D. | Chief Medical Officer | 1961 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 20. Jul 2026 | Happel David | President & CEO | Sell | 64,051 | 7.76 | 497,068 |
| 20. Jul 2026 | Rozek Elizabeth | Chief Legal & Admin. Officer | Sell | 10,545 | 7.76 | 81,832 |
| 20. Jul 2026 | Kemble George | Director | Sell | 18,844 | 7.46 | 140,529 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.